XBiotech

XBiotech CROIC

The Cash Return on Invested Capital (CROIC) of XBiotech (XBIT) as of Oct 28, 2026 is -28.65 %. In the previous year, Cash Return on Invested Capital (CROIC) was -16.76 % — a change of 70.93% (lower).

CROIC

-28.65 %

YoY

70.93%

Last updated:

Cash Return on Invested Capital (CROIC) of XBiotech is 2025 -28.65 % . Cash Return on Invested Capital (CROIC) of XBiotech was 2024 -16.76 % . It decreases by 70.93% lower compared to the previous year.

The XBiotech CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-40.24 USD
Jan 1, 2019
-2.44 USD
Jan 1, 2020
-19.76 USD
Jan 1, 2021
24.47 USD
Jan 1, 2022
-6.41 USD
Jan 1, 2023
-8.72 USD
Jan 1, 2024
-16.76 USD
Jan 1, 2025
-28.65 USD
The XBiotech CROIC history
YEARCROICYoY
-28.65 %+70.93%
-16.76 %+92.17%
-8.72 %+36.07%
-6.41 %-126.19%
24.47 %-223.87%
-19.76 %+708.05%
-2.44 %-93.92%
-40.24 %-30.94%
-58.27 %-42.57%
-101.46 %+139.27%
-42.41 %+91.13%
-22.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

XBiotech Stock analysis

What does XBiotech do? XBiotech Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutics for immune system disorders. The company was founded in 2008 in Texas, USA, and focuses on the production of monoclonal antibodies for the treatment of inflammatory diseases. The company's focus is on oncology and autoimmune diseases. By developing drugs that strengthen the body's immune defenses, the goal is to enable the immune system to fight diseases. This particularly involves T-cell-based immunotherapies that can be used in the treatment of cancer, autoimmune diseases, and infectious diseases. XBiotech has had an impressive track record in recent years. The company has obtained several FDA approvals for its products and has expanded rapidly into other parts of the world, including Europe and Asia. XBiotech's innovative business model involves developing therapeutic products that have a targeted effect on specific bodily processes. Currently, the company produces several therapeutics, including Xilonix, True Human, and hXBP-1. These products are used in the treatment of various inflammatory diseases, including Crohn's disease, diabetes, and other autoimmune diseases. XBiotech emphasizes that its products are fully human antibodies, unlike traditional antibodies, which have higher effectiveness and lower risk of side effects. Xilonix is a medication used for the treatment of metastatic colorectal cancer. It works by activating the body's immune system to more effectively fight cancer cells. True Human is a monoclonal antibody used in the treatment of inflammatory diseases such as Crohn's disease and rheumatoid arthritis. And hXBP-1 is a therapeutic protein developed to assist in the treatment of diabetes and obesity. XBiotech has also conducted several controlled studies to demonstrate the effectiveness of its products. These studies have shown the positive impact of XBiotech's products on patient health and have helped establish the company as a leading player in the field of immunotherapy. XBiotech has the potential to revolutionize the healthcare industry in the coming years. With its focus on developing innovative immunotherapies and its currently successful products on the market, the company has the opportunity to change the way we treat diseases. Overall, XBiotech is a biopharmaceutical company specializing in the development of drugs for the treatment of inflammatory diseases. The company has had an impressive track record in recent years and has the potential to change the medical landscape. XBiotech produces products that strengthen the body's immune system while minimizing the risk of side effects. With a focus on innovative immunotherapies, XBiotech is well positioned to make significant progress in the treatment of cancer, autoimmune diseases, and infectious diseases. XBiotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about XBiotech stock

Cash Return on Invested Capital (CROIC) of XBiotech is -28.65 % in 2025.

Cash Return on Invested Capital (CROIC) of XBiotech changed from -16.76 % to -28.65 %, representing a 70.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) XBiotech since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s XBiotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — XBiotech

All Key Metrics — XBiotech